Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
CorMedix is rated a 'Strong Buy' below ~$8.35, with ~114% upside to a $17.5 fair value based on DCF modeling. CRMD faces a 2027 revenue trough post-TDAPA, but I expect growth to reignite from 2027 to 2028, driven by DefenCath adoption and pipeline progress. Key mid-to-long-term catalysts include potential DaVita onboarding, federal market expansion, and pipeline assets like DefenCath TPN and REZZAYO.
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
CorMedix NASDAQ: CRMD CEO Joe said the company is preparing for several potential commercial and regulatory catalysts across its infectious disease and dialysis-related portfolio, including a possible expansion of REZZAYO into fungal infection prophylaxis and continued work to sustain DefenCath utilization through changes in federal reimbursement.
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix Q1 Earnings Call Highlights
CorMedix NASDAQ: CRMD reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while management raised its full-year financial outlook and outlined key pipeline developments.
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.3 per share a year ago.
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
CorMedix (CRMD) Lags Q4 Earnings Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.61 per share, missing the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.22 per share a year ago.
